Background. Retinopathy of prematurity (RP) remains one of the causes of bilateral visual impairment in children. The main cause of RP is not only an imbalance of factors regulating angiogenesis, but also oxidative stress.
Objective. Meta-analysis of studies of the pentahydroxyethylnaphthoquinone, which was developed, patented and has a full production cycle in the Russian Federation; evaluation of the effectiveness of its use in premature newborns to prevent the development and progression of retinopathy.
Methods. The effectiveness of pentahydroxyethylnaphthoquinone in premature newborns to prevent the development and progression of retinopathy was evaluated.
Results. A pilot meta-analysis on the use of pentahydroxyethylnaphthoquinone indicates its benefits in preventing the development and progression of retinopathy. The results depend on the methodology and methods of the study, and therefore should be taken with caution. At the same time, the findings correlate with the positive experience of using this drug in the Russian Federation.
Conclusion. The minimum number of studies included in the meta-analysis allows for indicative results. With a large number of studies in different groups of patients, it is possible that different results will be obtained.

Keywords: pentahydroxyethylnaphthoquinone, premature child, retinopathy of prematurity